In our study, we performed a therapeutic intervention after wet AMD onset and observed that reducing VEGFA expression by locally delivering a gene‐editing system in the early stages of CNV development is effective in treating CNV in a short time. The gene discussed is VEGFA; the disease is wet macular degeneration.